Sangamo Therapeutics Inc.
04/29/2026 | Press release | Distributed by Public on 04/29/2026 06:37
Material Event (Form 8-K)
Item 8.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously reported, on April 30, 2025, Sangamo Therapeutics, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that because the closing bid price for the Company's common stock had fallen below $1.00 per share for 30 consecutive business days, it no longer complied with the minimum bid price requirement (the "Minimum Bid Price Requirement") for continued listing under Nasdaq Listing Rule 5550(a)(2) on The Nasdaq Capital Market. The Company was provided until October 27, 2025 to regain compliance with the Minimum Bid Price Requirement. Also as previously reported, on October 29, 2025, the Company received an additional notification from the Staff that while the Company had not regained compliance with the Minimum Bid Price Requirement, it was eligible for an additional 180-day compliance period, or until April 27, 2026, to regain compliance with the Minimum Bid Price Requirement.
On April 28, 2026, the Company received a written notification (the "Delisting Notice") from the Staff of its determination to delist the Company's common stock as a result of the Company's ongoing failure to comply with the Minimum Bid Price Requirement. The Delisting Notice also stated that trading in the Company's common stock on The Nasdaq Capital Market will be suspended at the open of trading on May 5, 2026.
The Company plans to request a hearing before a Nasdaq Hearings Panel (the "Panel") pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series for the purpose of appealing the Staff's delisting determination. However, pursuant to Nasdaq Listing Rule 5815(a)(1)(B)(ii)(d), a timely request for a hearing will stay delisting but will not stay the trading suspension of the Company's common stock. The Company's common stock will remain suspended from trading on The Nasdaq Capital Market unless the Panel's decision issued after the hearing ultimately determines to reinstate trading of the securities on The Nasdaq Capital Market.
The Company has received approval for its common stock to be quoted on the OTCQB Venture Market, an over-the-counter market operated by OTC Markets Group, and expects trading on OTCQB to commence on May 5, 2026 under its existing symbol "SGMO."
Sangamo Therapeutics Inc. published this content on April 29, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 29, 2026 at 12:38 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]